Skip to main content

5 articles related to "Adverse Event Management"

No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.
No matches to your query could be found. Try another search term.

Articles

Original Research

Published on 14 Jan 2026

Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer

in Health Economics

Jie Huang
Wei Zhang
Bangyu Zhang

Frontiers in Public Health

doi 10.3389/fpubh.2025.1754642

838 views

Review

Published on 26 Nov 2024

Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement

in Hematologic Malignancies

Guido Lancman
Kevin Song
Darrell White
Tina Crosbie
Ismail Sharif
Marianne Emond
Muhammad Saleem Raza
Martine Elias
Rayan Kaedbey
Michael P. Chu

Frontiers in Oncology

doi 10.3389/fonc.2024.1446995

7,762 views
2 citations

Perspective

Published on 01 Jul 2025

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects

in Cancer Immunity and Immunotherapy

Jia-Wen Wang
Ying-Fa Feng
Jia-Hui Liu

Frontiers in Immunology

doi 10.3389/fimmu.2025.1629879

5,180 views
2 citations

Original Research

Published on 22 Jul 2022

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China

in Cancer Immunity and Immunotherapy

Ting Chen
Ruixiang Xie
Qiuling Zhao
Hongfu Cai
Lin Yang

Frontiers in Oncology

doi 10.3389/fonc.2022.746526

4,170 views
9 citations

Original Research

Published on 21 Sep 2016

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice

in Drugs Outcomes Research and Policies

Lonneke Timmers
Christel C. L. M. Boons
Dirk Mangnus
Peter M. Van de Ven
Pieter H. Van den Berg
Aart Beeker
Eleonora L. Swart
Richard J. Honeywell
Godefridus J. Peters
Epie Boven

Frontiers in Pharmacology

doi 10.3389/fphar.2016.00310

10,763 views
24 citations